Signal-1, Signal-2, and other co-stimulatory signals at the interface of T cell and APC is called the "immunological synapse." Grakoui et al. have demonstrated that the formation of the immunological synapse is a dynamic process (Grakoui et al., 1999) . Initially, TCR/MHC-antigen complexes are found peripherally in a ring shape of the nascent synapse while LFA-1/ICAM-1 molecules congregate toward the central cell-cell contacting region. As T-cell activation proceeds, both molecular complexes are re-arranged (translocated) into a bull's eye pattern with a central supramolecular activation cluster (cSMAC) surrounded by a peripheral supramolecular activation cluster (pSMAC) (Monks et al., 1998; Grakoui et al., 1999; Lee et al., 2002) .
To develop a novel method to alter immune response in an antigen-specific manner, we have designed a bifunctional peptide inhibitor (BPI) that targets the immunological synapse.
The BPI is made of the following three peptide portions: (a) antigen epitope peptide and (b) ICAM-1-binding peptide, which are conjugated via (c) a spacer peptide. Our group has previously discovered the ICAM-1-binding peptide, named LABL, derived from α L integrin
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JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on August 15, 2017 jpet.aspetjournals.org Downloaded from (CD11a [237] [238] [239] [240] [241] [242] [243] [244] [245] [246] ) (Yusuf-Makagiansar et al., 2001a; Yusuf-Makagiansar et al., 2001b) . We have shown that LABL binds to domain-1 of ICAM-1 and can block T-cell adhesion to intestinal mucosa cell monolayers (Yusuf-Makagiansar et al., 2001a; Yusuf-Makagiansar et al., 2001b; Yusuf-Makagiansar and Siahaan, 2001 ) and pancreatic islet microvascular endothelium (Huang et al., 2005) . Therefore, our hypothesis is that the antigen epitope peptide and LABL from a BPI molecule bind to MHC and ICAM-1, respectively, on the surface of APC. By bridging these target molecules, BPI prevents the translocation and segregation of Signal-1 and Signal-2, thereby inhibiting the immunological synapse formation (Fig. 1) . In a parallel study, we have also demonstrated that GAD-BPI with glutamic acid decarboxylase (GAD) epitope for type-1 diabetes suppresses invasive insulitis and hyperglycemia in non-obese diabetic mice (manuscript submitted).
In this work, we have designed and developed PLP-BPI (Table 1) (Tuohy et al., 1989) . The therapeutic activity of PLP-BPI was evaluated by suppressing experimental autoimmune encephalomyelitis (EAE) in mice, a model for human MS. We also studied the potential activity of PLP-BPI in inducing fatal anaphylaxis, which is one of the problems in using antigen-derived peptides to treat autoimmune diseases.
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Peptide synthesis
Peptides used in the present study are listed in Table 1 . The peptides were synthesized with 9-fluorenylmethyloxycarbonyl-protected amino acid chemistry on appropriate PEG-PS™ resins (Applied Biosystems, Foster City, CA) using the automated peptide synthesis system (Pioneer TM : PerSeptive Biosystems, Framingham, MA). Cleavage of the peptides from the resin and removal of the protecting groups from the side-chain were carried out using trifluoroacetic acid with scavengers. The crude peptides were purified by reversed-phase HPLC using a C 18 column with a gradient of solvent A (95%/5% = H 2 O (0.1% TFA)/acetonitrile) and solvent B (100% acetonitrile). The purity of the peptide was analyzed by analytical HPLC using an analytical C 18 column. The identity of the synthesized peptide was confirmed by matrix assisted laser desorption/ionization-time of flight mass spectrometry.
Induction of EAE and therapeutic study
Five-to seven-wk-old SJL/J female mice were immunized s. (20 µg/ml) for 0, 48, or 72 h. The cells were then treated with ionomycin (50 ng/ml) and phorbol myristate acetate (500 ng/ml) for 4 h and with brefeldin A (10 µg/ml) for the last 2 h. Next, the cells were stained with various anti-mouse antibodies followed by analysis with a flow cytometer (FACScan, BD, Franklin Lakes, NJ). The antibodies used were: for surface staining, PerCP-Cy5.5-anti-CD4 (L3T4); FITC-anti-CD25 (7D4); FITC-anti-CD49b (DX5); or biotinylated anti-TGF-β1 followed by PE-Streptavidin, and for intracellular staining, PE-anti-IL-4 (BVD4-1D11); PE-anti-IL-10 (JES5-16E3); or PE-anti-IFN-γ (XMG1.2) (the antibodies were purchased from BD Biosciences (San Jose, CA) except biotinylated anti-TGF-β1, which was from R&D System (Minneapolis, MN)).
Statistic analysis
Statistical differences among the groups in clinical disease score on each day were analyzed by Mann-Whitney's U test. Statistical differences among the groups in body weight were analyzed by one-way analysis of variance (ANOVA) followed by Fisher's least significant difference.
RESULTS

Suppression of EAE by PLP-BPI
In vivo therapeutic activity of PLP-BPI was evaluated in an EAE model induced in SJL/J mice. The mice showed disease signs of EAE such as weakness or paralysis of their tail and limbs as well as losing body weight, which become apparent around days 8-12 following immunization. As shown in Fig. 2 , i.v. injections of PLP-BPI inhibited the disease progression of EAE more effectively than did any other peptides tested, including PLP 139-151 , LABL (CD11a 237-246 ), and ovalbumin (OVA)-BPI ( Fig. 2 ). PLP-BPI-treated mice had very low EAE clinical scores throughout the study (Fig. 2A) ; their scores were significantly lower than those of groups treated with phosphate-buffered saline (PBS), OVA-BPI, LABL, and PLP L144, R147 at the peak of the disease (days 12-17, supplemental Table 1 ). The PLP-BPI-treated mice had minimum loss of body weight ( Fig. 2B ) compared to the other groups (days 15-19, supplemental Table 1 ). In addition, 30% of the mice receiving PLP-BPI never developed EAE during the course of study; even the EAE-positive mice in this group showed delayed disease onset compared with other groups (Fig. 2C ). TCR antagonist peptide PLP L144, R147 (Kuchroo et al., 1994) , which was given on day 7 by i.p. injection (500 µg/mouse), produced the worst disease scores under this experimental condition.
To evaluate the importance of "BPI structure," including the necessity of PLP 139-151 and LABL peptides and the role of linking the two peptides via a spacer, the activity of PLP-BPI was compared with that of PLP-BPI sLABL , VP2-BPI, and unlinked mixture of PLP 139-151 and LABL ( from the in vivo therapeutic study are shown in Fig. 3 and Table 2 . The PLP-BPI-treated animals had significantly lower scores than those of PBS-and VP2-BPI-treated groups at days 12-21 Table 2 ). PLP-BPI-treated mice had minimum loss of body weight even at the peak of the disease (Fig. 3B ), significantly lower than those of any other groups on days 15-18 (see Supplemental Table 2 ). In addition, PLP-BPI-treated mice had the lowest EAE incidence (Fig. 3C ). Although PLP-BPI sLABL or the mixture of PLP 139-151 and LABL has moderate activity, PLP-BPI is the best molecule to suppress EAE, delay the disease onset, and shorten the disease period (Table 2 ). Significant but moderate EAE-suppressing effects were also observed in another type of 'scrambled LABL'-containing PLP-BPI sLABL (HSLGKWLGHPDKF-AcGAcGAc-DADTTSEIGG) as well as PLP-polyG which contains deca-glycine instead of LABL (HSLGKWLGHPDKF-AcGAcGAc-GGGGGGGGGG) (data not shown). These results suggest that the linked structure of PLP-BPI and the sequences of both PLP 139-151 and LABL peptides in PLP-BPI are important for the suppressing activity of BPI.
PLP-BPI activity in inducing anaphylactic reactions
One of the most important issues in treating autoimmune diseases with multiple injections of antigen-related peptides is the possibility of induction of anaphylaxis (Pedotti et al., 2001; Liu et al., 2002; Pedotti et al., 2003; Smith et al., 2005 incidence of anaphylaxis in PLP-BPI is presumably due to the structure of this molecule with a linker and another peptide moiety at the C-terminal.
Effect of PLP-BPI treatment on regulatory T cell characteristics
To (Kuchroo et al., 1994; Samson and Smilek, 1995; Heijmans et al., 2005; Margot et al., 2005; Stern et al., 2005) , oligomerized PLP 139-151 (Falk et al., 2000) , mannosylated PLP 139-151 (Luca et al., 2005) , PLP-or myelin basic protein (MBP)-derived peptide coupled onto splenocytes (Vanderlugt et al., 2000; Smith et al., 2005) , aggregated Ig-PLP 139-151 chimera (Legge et al., 2000; Yu et al., 2005) , and soluble MHC-PLP 139-151 construct (Wang et al., 2006) .
A synthetic copolymer based on four amino acids of MBP (Glatiramer Acetate or Copaxone) is currently being used to treat MS patients; this molecule modulates Signal-1 as APL to generate Th2 immunity (Johnson et al., 1995; Neuhaus et al., 2001) . Similarly, T-cell activation can be suppressed by inhibiting Signal-2 formation with anti-CD28 Fab fragment (Perrin et al., 1999) , CTLA-4-Ig fusion protein (Khoury et al., 1995) , anti-CD40L antibody (Gerritse et al., 1996) , anti-α 4 integrin (Natalizumab or Tysabri) (Langer-Gould et al., 2005) , and CD28-derived peptidomimetics (Srinivasan et al., 2002) . Unfortunately, these treatments suppress the general immune response, which is not antigen-or disease-specific. In the case of Tysabri, it was temporarily withdrawn from the market because several patients treated with this drug were infected by JC virus infection that causes progressive multifocal leukoencephalopathy TGF-β-, IL-4-, and IL-10-producing CD4 + CD25 + T cells were significantly increased in PLP-BPI-treated mice, suggesting that the Th2 cytokine-producing CD4 + CD25 + regulatory T cells are in part responsible for the BPI action (Fig. 4) . This is consistent with previous reports that indicate the involvement of Th2 cytokine-producing CD4 + CD25 + regulatory T cells in resistance to and recovery from EAE (Reddy et al., 2004; Yu et al., 2005; Zhang et al., 2006 peptides has previously been shown to induce immune tolerance in animal models (Karin et al., 1994; Liblau et al., 1996; Bercovici et al., 1999; Wildbaum et al., 2002) . It has been suggested that the induction of immune tolerance involves elicitation of regulatory T cells, peripheral deletion of CD4 + T cells, and TCR desensitization (Liblau et al., 1996; Bercovici et al., 1999; Wildbaum et al., 2002) . Unfortunately, the TCR antagonist peptide PLP L144, R147 (Kuchroo et al., 1994) , which we intended to use as a positive control, worsened the disease. Differences in experimental conditions such as timing of peptide injection may account for this discrepancy. It also seems that treatment with LABL peptide alone exacerbates the disease. This might be in part because of non-specific inhibition of LFA-1/ICAM-1 interactions. Treatment with anti-LFA-1 monoclonal antibody augments disease severity and mortality in EAE mice (Welsh et al., 1993; Rose et al., 1999) .
There that peptides are believed to be less antigenic and safer than whole proteins due to their relatively small size, anaphylactic reactions to several peptides have been clearly described (Pedotti et al., 2001; Liu et al., 2002; Pedotti et al., 2003; Smith et al., 2005) . The development of MBP-derived APL for treatment of MS has been suspended because of hypersensitivity reactions in patients in phase II clinical trials (Bielekova et al., 2000; Kappos et al., 2000) . In humans, the mechanism of anaphylactic response is considered to be antigen-induced (Inamura et al., 1998) . Thus, inhibition of LFA-1/ICAM-1 interactions by LABL peptide at the site of IgE antigen recognition might be, in part, the reason for the lower anaphylactic potential of PLP-BPI.
In conclusion, PLP-BPI effectively inhibited the disease severity and incidence of EAE.
Although anaphylaxis was not completely suppressed by PLP-BPI-treatment, it appears that PLP-BPI is safer than the parental antigenic peptide alone There are significant differences between PLP-BPI-and PBS-treated groups in clinical disease score (P < 0.05, through days 12-19), body weight (P < 0.05, through days 14-23), and disease incidence (P < 0.01). The results of other combinations of statistic comparisons are shown in supplemental Table 1 . (Kuchroo et al., 1994 ) has mutation at residues 144 (W>L) and 147 (H>R). 
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